comparemela.com

Latest Breaking News On - Gigi feng - Page 9 : comparemela.com

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongSan diegoEmilie wuAndrew zhuGigi fengJingwu zangJohn longJielun zhuWeimin tangCompany americanPrnewswire the company nasdaqCompany adssPiacente group incExchange commissionChief financial officer john long

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongSan diegoEmilie wuAndrew zhuGigi fengJingwu zangJohn longJielun zhuWeimin tangCompany americanPrnewswire the company nasdaqCompany adssPiacente group incExchange commissionChief financial officer john long

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company com.

United statesHong kongSan diegoSouth koreaEmilie wuAndrew zhuGigi fengJohn longCompany nasdaqDepartment of oncology at shanghai east hospitalPiacente group incExchange commissionProfessor ye guoDeputy directorShanghai east hospitalPrivate securities litigation reform act

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongSan diegoSouth koreaEmilie wuAndrew zhuGigi fengJohn longCompany nasdaqDepartment of oncology at shanghai east hospitalPiacente group incExchange commissionProfessor ye guoDeputy directorShanghai east hospitalPrivate securities litigation reform act

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesHong kongSan diegoSouth koreaEmilie wuAndrew zhuGigi fengJohn longCompany nasdaqDepartment of oncology at shanghai east hospitalPiacente group incExchange commissionProfessor ye guoDeputy directorShanghai east hospitalPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.